Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedSep 28, 2025
DataAggregated Company Financials
Companies294
  • 7D-1.2%
  • 3M1.4%
  • 1Y-11.3%
  • YTD-2.4%

Over the last 7 days, the Pharma industry has dropped 1.2%, driven by Eli Lilly declining 3.7%. However, the industry is down 11% over the past year. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 28 Sep 2025US$1.7tUS$387.9bUS$60.9b18.3x28.7x4.5x
Tue, 26 Aug 2025US$1.7tUS$387.8bUS$61.0b19.5x28.7x4.5x
Thu, 24 Jul 2025US$1.8tUS$384.0bUS$62.1b18.3x28.5x4.6x
Sat, 21 Jun 2025US$1.7tUS$382.7bUS$61.2b17.6x28.4x4.5x
Mon, 19 May 2025US$1.7tUS$382.6bUS$61.2b17.2x27.4x4.4x
Wed, 16 Apr 2025US$1.7tUS$380.5bUS$48.4b15x34.5x4.4x
Fri, 14 Mar 2025US$1.9tUS$380.5bUS$35.2b16.8x52.8x4.9x
Sun, 09 Feb 2025US$1.9tUS$380.7bUS$39.1b19.5x48x4.9x
Tue, 07 Jan 2025US$1.8tUS$369.3bUS$31.3b18x57.4x4.9x
Thu, 05 Dec 2024US$1.9tUS$373.8bUS$30.6b19.4x60.9x5x
Sat, 02 Nov 2024US$1.9tUS$373.2bUS$29.3b19.6x65.3x5.1x
Mon, 30 Sep 2024US$2.0tUS$364.1bUS$25.3b19.1x78.5x5.4x
Wed, 28 Aug 2024US$2.0tUS$362.1bUS$21.8b17.8x93.9x5.7x
Fri, 26 Jul 2024US$2.0tUS$356.5bUS$13.2b16.2x149.2x5.5x
Sun, 23 Jun 2024US$2.0tUS$358.2bUS$14.1b16.5x139x5.5x
Tue, 21 May 2024US$1.9tUS$358.3bUS$14.0b18.2x133.7x5.2x
Thu, 18 Apr 2024US$1.8tUS$357.7bUS$29.9b20.4x59.9x5x
Sat, 16 Mar 2024US$1.9tUS$355.4bUS$22.5b19.8x83x5.2x
Mon, 12 Feb 2024US$1.9tUS$354.7bUS$22.8b31.7x81.6x5.2x
Wed, 10 Jan 2024US$1.8tUS$375.2bUS$33.9b27.8x52.3x4.7x
Fri, 08 Dec 2023US$1.7tUS$375.1bUS$33.9b26.7x49x4.4x
Sun, 05 Nov 2023US$1.6tUS$376.9bUS$33.9b18.5x48.1x4.3x
Tue, 03 Oct 2023US$1.6tUS$381.8bUS$43.8b19x37.7x4.3x
Thu, 31 Aug 2023US$1.7tUS$381.4bUS$43.8b21.1x39.6x4.5x
Sat, 29 Jul 2023US$1.7tUS$393.6bUS$61.5b18.5x27.8x4.3x
Mon, 26 Jun 2023US$1.8tUS$392.8bUS$60.1b18.9x29.2x4.5x
Wed, 24 May 2023US$1.7tUS$393.0bUS$60.5b18.5x28.2x4.3x
Fri, 21 Apr 2023US$1.7tUS$402.6bUS$63.3b17.4x26.1x4.1x
Sun, 19 Mar 2023US$1.5tUS$401.1bUS$69.3b15.5x22.2x3.8x
Tue, 14 Feb 2023US$1.7tUS$401.8bUS$68.8b18.6x24.3x4.2x
Thu, 12 Jan 2023US$1.7tUS$403.7bUS$70.6b17.4x24.5x4.3x
Sat, 10 Dec 2022US$1.8tUS$403.7bUS$70.7b16.5x24.8x4.3x
Mon, 07 Nov 2022US$1.7tUS$403.8bUS$71.4b14.3x23.5x4.2x
Wed, 05 Oct 2022US$1.6tUS$403.0bUS$71.3b13.2x22.3x3.9x
Price to Earnings Ratio

22.3x


Total Market Cap: US$1.6tTotal Earnings: US$71.3bTotal Revenue: US$403.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.4x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 28.7x which is lower than its 3-year average PE of 52.4x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 5.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.58%
Healthcare-0.77%
Pharma-1.22%
Pharma-1.22%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$179.712.0%
+US$8.5b		11.3%PE19.1x
CRNX Crinetics PharmaceuticalsUS$45.9135.4%
+US$1.1b		-9.5%PS3106x
MBX MBX BiosciencesUS$17.5175.1%
+US$446.8m		-26.9%PB3.6x
CORT Corcept TherapeuticsUS$83.874.2%
+US$353.0m		90.9%PE66.9x
ELAN Elanco Animal HealthUS$19.612.1%
+US$203.7m		36.9%PE22.4x

Latest News

CRNX
US$45.91
Crinetics Pharmaceuticals
7D
35.4%
1Y
-9.5%
MBX
US$17.51
MBX Biosciences
7D
75.1%
1Y
-26.9%
LLY
US$724.54
Eli Lilly
7D
-3.7%
1Y
-17.5%
PFE
US$23.76
Pfizer
7D
-1.1%
1Y
-18.3%
BMY
US$44.12
Bristol-Myers Squibb
7D
-2.0%
1Y
-13.3%
JNJ
US$179.71
Johnson & Johnson
7D
2.0%
1Y
11.3%

US 55 Billion Investment Will Drive Breakthrough Therapies

Analysts raised Johnson & Johnson’s price target to $179.64, reflecting confidence in robust performance of its Innovative Medicine portfolio and pipeline assets, improved earnings guidance, and resilient management of patent challenges, partly offset by regulatory uncertainty. Analyst Commentary Bullish analysts view Johnson & Johnson's handling of the Stelara loss of exclusivity as strong, emphasizing confidence in new growth led by its Innovative Medicine business and existing product portfolio (Tremfya, Darzalex, Spravato, Caplyta).
ZTS
US$143.50
Zoetis
7D
-1.6%
1Y
-26.3%
ELAN
US$19.61
Elanco Animal Health
7D
2.1%
1Y
36.9%
CORT
US$83.87
Corcept Therapeutics
7D
4.2%
1Y
90.9%
VTRS
US$9.52
Viatris
7D
-3.8%
1Y
-17.6%
MRK
US$78.56
Merck
7D
-3.6%
1Y
-30.9%
MAZE
US$27.00
Maze Therapeutics
7D
17.7%
1Y
n/a
RPRX
US$35.04
Royalty Pharma
7D
-3.3%
1Y
24.2%

Emerging Therapies And Licensing Will Expand Royalty Opportunities

Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.
EWTX
US$16.05
Edgewise Therapeutics
7D
12.6%
1Y
-38.5%
ZYBT
US$1.84
Zhengye Biotechnology Holding
7D
-80.1%
1Y
n/a

Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) 26% Price Boost Is Out Of Tune With Revenues

Aug 24
Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) 26% Price Boost Is Out Of Tune With Revenues
INDV
US$23.92
Indivior
7D
6.3%
1Y
138.2%